Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Natera is a rapidly-growing diagnostics company with proprietary bioinformatics an...
Natera is a rapidly-growing diagnostics company...
HelloAva is an innovative new platform that uses AI technology to provide a person...
HelloAva is an innovative new platform that use...
Checkpoint Therapeutics, Inc. (âCheckpointâ) is a clinical-stage, immuno-oncol...
Checkpoint Therapeutics, Inc. (âCheckpointâ...
Natera is a rapidly-growing diagnostics company with proprietary bioinformatics an...
Natera is a rapidly-growing diagnostics company...
Nature is full of untapped potential. Microbes are a proven but underused resource...
Nature is full of untapped potential. Microbes ...
Solid Biosciences is a life science company focused solely on finding meaningful t...
Solid Biosciences is a life science company foc...
Generex Biotechnology is an integrated healthcare holding company with end-to-end ...
Generex Biotechnology is an integrated healthca...
Join the National Investor Network and get the latest information with your interests in mind.